AI in Clinical Trials Market - Global Forecast to 2030

Table of Content

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 STUDY SCOPE 34
1.3.1 SEGMENTS CONSIDERED 34
1.3.2 INCLUSIONS & EXCLUSIONS 35
1.3.3 YEARS CONSIDERED 37
1.3.4 CURRENCY CONSIDERED 37
1.4 STAKEHOLDERS 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.1.1 Key sources for secondary data 40
2.1.1.2 Key data from secondary sources 41
2.1.2 PRIMARY DATA 41
2.1.2.1 Key sources for primary data 42
2.1.2.2 Objectives of primary research 42
2.1.2.3 Key data from primary sources 43
2.1.2.4 Key insights from primary experts 44
2.2 MARKET SIZE ESTIMATION 45
2.2.1 SUPPLY-SIDE REVENUE SHARE ANALYSIS 45
2.2.2 PARENT MARKET APPROACH 45
2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 45
2.2.4 MARKET SEGMENT ASSESSMENT 46
2.2.5 GEOGRAPHIC MARKET ASSESSMENT 47
2.3 DATA TRIANGULATION 49
2.4 MARKET SHARE ESTIMATION 50
2.5 STUDY ASSUMPTIONS 50
2.6 RESEARCH LIMITATIONS 50
2.6.1 METHODOLOGY-RELATED LIMITATIONS 50
2.6.2 SCOPE-RELATED LIMITATIONS 50
2.7 RISK ASSESSMENT 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHTS 59
4.1 AI IN CLINICAL TRIALS MARKET OVERVIEW 59
4.2 AI IN CLINICAL TRIALS MARKET, BY REGION 60
4.3 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER AND COUNTRY 61
4.4 AI IN CLINICAL TRIALS MARKET: GEOGRAPHICAL SNAPSHOT 62
4.5 AI IN CLINICAL TRIALS MARKET: DEVELOPED VS. EMERGING MARKETS 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.3 MARKET DYNAMICS 65
5.3.1 DRIVERS 65
5.3.1.1 Increasing demand for personalized treatments 65
5.3.1.2 Support for decentralized and global trials 67
5.3.1.3 Regulatory compliance and ethical considerations 67
5.3.1.4 Automated document review for better regulatory compliance 68
5.3.1.5 Focus on real-time data management and analysis 68
5.3.2 RESTRAINTS 69
5.3.2.1 Data privacy and security concerns 69
5.3.2.2 Integration challenges with legacy systems and resistance from healthcare professionals 70
5.3.2.3 High implementation cost and need for skilled AI professionals 71
5.3.3 OPPORTUNITIES 71
5.3.3.1 Use of predictive analytics in clinical trials 71
5.3.3.2 Development of virtual control arms for faster trials 72
5.3.3.3 Integrating natural language processing into clinical trials for data extraction 73
5.3.4 CHALLENGES 73
5.3.4.1 Addressing algorithm bias and fairness 73
5.3.4.2 Insufficient technical expertise in AI-based solutions 74
5.4 INDUSTRY TRENDS 74
5.4.1 INCREASING ADOPTION OF DECENTRALIZED CLINICAL TRIALS 74
5.4.2 RISING FOCUS ON AI-POWERED PATIENT RECRUITMENT AND RETENTION 74
5.5 ECOSYSTEM ANALYSIS 75
5.6 CASE STUDY ANALYSIS 75
5.6.1 AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT 75
5.6.2 REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS 76
5.6.3 BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS 77
5.7 VALUE CHAIN ANALYSIS 77
5.8 PORTER’S FIVE FORCES ANALYSIS 79
5.8.1 BARGAINING POWER OF SUPPLIERS 80
5.8.2 BARGAINING POWER OF BUYERS 80
5.8.3 THREAT OF SUBSTITUTES 81
5.8.4 THREAT OF NEW ENTRANTS 81
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.9 KEY STAKEHOLDERS & BUYING CRITERIA 82
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
5.9.2 KEY BUYING CRITERIA 83
5.10 REGULATORY LANDSCAPE 83
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
5.10.2 REGULATORY FRAMEWORK 84
5.11 PATENT ANALYSIS 87
5.11.1 PATENT PUBLICATION TRENDS FOR AI IN CLINICAL TRIALS 87
5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS 88
5.12 TECHNOLOGY ANALYSIS 90
5.12.1 KEY TECHNOLOGIES 90
5.12.1.1 Machine learning 90
5.12.1.2 Natural language processing 90
5.12.1.3 Computer vision 90
5.12.2 COMPLEMENTARY TECHNOLOGIES 90
5.12.2.1 Internet of things 90
5.12.2.2 Cloud computing 90
5.12.3 ADJACENT TECHNOLOGIES 91
5.12.3.1 Advanced genomics 91
5.13 PRICING ANALYSIS 91
5.13.1 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023 91
5.13.2 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022–2024 92
5.14 KEY CONFERENCES & EVENTS, 2024–2025 92
5.15 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 93
5.16 UNMET NEEDS AND END-USER EXPECTATIONS 94
5.16.1 UNMET NEEDS 94
5.16.2 END-USER EXPECTATIONS 95
5.17 INVESTMENT & FUNDING SCENARIO 95
5.18 IMPACT OF AI/GEN AI ON AI IN CLINICAL TRIALS MARKET 96
5.18.1 KEY USE CASES 97
5.18.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 97
5.18.2.1 Case study 97
5.18.2.2 Clinical trials market 98
5.18.2.3 eClinical solutions market 98
5.18.2.4 AI in biotechnology market 99
5.18.3 USERS READINESS AND IMPACT ASSESSMENT 99
5.18.3.1 User readiness 99
5.18.3.1.1 Pharmaceutical & biopharmaceutical companies 99
5.18.3.1.2 Contract research organizations 99
5.18.3.2 Impact assessment 99
5.18.3.2.1 User A: Healthcare providers 99
5.18.3.2.2 User B: Research institutes & laboratories 100
6 AI IN CLINICAL TRIALS MARKET, BY OFFERING 101
6.1 INTRODUCTION 102
6.2 END-TO-END SOLUTIONS 102
6.2.1 COST-EFFECTIVENESS, IMPROVED EFFICIENCY, AND REDUCED HUMAN ERRORS TO DRIVE ADOPTION IN CLINICAL TRIALS 102
6.3 NICHE SOLUTIONS 103
6.3.1 HIGH FAILURE RATES OF CLINICAL TRIALS AND NEED FOR STREAMLINED PROCESSES TO FUEL MARKET GROWTH 103
6.4 TECHNOLOGY PROVIDERS 104
6.4.1 NEED TO ACCELERATE DRUG DEVELOPMENT PROCESSES AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH 104
6.5 SERVICES 105
6.5.1 CONSULTING SERVICES 106
6.5.1.1 Consulting services to optimize trial design, enhance patient recruitment, and improve data management 106
6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT 107
6.5.2.1 Need for smooth integration and optimization of AI technologies to boost segment growth 107
6.5.3 TRAINING & EDUCATION SERVICES 108
6.5.3.1 Need for skilled talent for managing complex AI systems to augment segment growth 108
6.5.4 POST-SALES & MAINTENANCE SERVICES 109
6.5.4.1 Development of complex AI systems and need for continuous improvement in AI algorithms to drive segment growth 109
7 AI IN CLINICAL TRIALS MARKET, BY FUNCTION 111
7.1 INTRODUCTION 112
7.2 PATIENT RECRUITMENT 112
7.2.1 PATIENT IDENTIFICATION & SCREENING 114
7.2.1.1 Reduced patient screening time and better accuracy than human clinicians to drive market 114
7.2.2 PATIENT ENGAGEMENT & RETENTION 115
7.2.2.1 Better personalized communication and support for clinical trials to propel market growth 115
7.2.3 SITE OPTIMIZATION 116
7.2.3.1 Cost-effective and improved participant recruitment and retention to fuel segment growth 116
7.3 TRIAL DESIGN OPTIMIZATION 117
7.3.1 WORKFLOW MANAGEMENT 118
7.3.1.1 Effective real-time tracking, automated reporting, and milestone monitoring to spur segment growth 118
7.3.2 PREDICTIVE MODELING 119
7.3.2.1 Ability to optimize trial design, predict risks, and identify effective treatment protocols to drive segment 119
7.3.3 RISK MANAGEMENT 120
7.3.3.1 AI-driven solutions for risk prediction to improve patient safety and data integrity 120
7.4 DATA MANAGEMENT & QUALITY CONTROL 121
7.4.1 FOCUS ON MAINTAINING DATA ACCURACY AND INTEGRITY IN CLINICAL TRIALS TO BOOST ADOPTION 121
7.5 ADVERSE EVENT PREDICTION & DETECTION 122
7.5.1 MITIGATING RISKS AND HARNESSING AI-DRIVEN ADVERSE EVENT DETECTION TO SPUR MARKET GROWTH 122
7.6 DRUG REPURPOSING 123
7.6.1 DRUG REPURPOSING TO VALIDATE HYPOTHESES AGAINST REAL-TIME PATIENT DATA IN RARE DISEASES 123
7.7 REGULATORY COMPLIANCE 124
7.7.1 COMPLEXITY OF GLOBAL REGULATORY ENVIRONMENTS AND NEED FOR FASTER DRUG APPROVALS TO AID MARKET GROWTH 124
8 AI IN CLINICAL TRIALS MARKET, BY PHASE 126
8.1 INTRODUCTION 127
8.2 PHASE I CLINICAL TRIALS 127
8.2.1 FASTER PATIENT IDENTIFICATION AND RECRUITMENT TO PROPEL ADOPTION OF AI 127
8.3 PHASE II CLINICAL TRIALS 128
8.3.1 NEED FOR ACCURATE PREDICTION OF OPTIMAL DOSAGE IN PHASE II TRIALS TO BOOST USE OF AI 128
8.4 PHASE III CLINICAL TRIALS 129
8.4.1 NEED TO CHECK DRUG EFFICACY AND MONITOR ADVERSE REACTIONS TO AUGMENT MARKET GROWTH 129
8.5 PHASE IV CLINICAL TRIALS 130
8.5.1 AI TO ASSESS SAFETY AND LONG-TERM OUTCOMES OF TREATMENT IN LARGER PATIENT POPULATION UNDER PHASE IV TRIALS 130
9 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 132
9.1 INTRODUCTION 133
9.2 CLOUD-BASED SOLUTIONS 133
9.2.1 PUBLIC CLOUD-BASED SOLUTIONS 135
9.2.1.1 Reduced need for costly on-premises infrastructure and better regulatory compliance to fuel adoption 135
9.2.2 PRIVATE CLOUD-BASED SOLUTIONS 136
9.2.2.1 Better security and personalization for sensitive data to propel segment growth 136
9.2.3 MULTI CLOUD-BASED SOLUTIONS 137
9.2.3.1 Use of advanced predictive modeling for patient recruitment and site performance optimization to drive market 137
9.2.4 HYBRID CLOUD-BASED SOLUTIONS 138
9.2.4.1 Better flexibility in data management to reduce resource requirements in clinical trials 138
9.3 ON-PREMISES SOLUTIONS 139
9.3.1 ON-PREMISES SOLUTIONS TO OFFER SECURE ENVIRONMENT FOR MANAGING SENSITIVE DATA AND RUNNING COMPLEX ALGORITHMS 139
10 AI IN CLINICAL TRIALS MARKET, BY INDICATION 140
10.1 INTRODUCTION 141
10.2 ONCOLOGY 141
10.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE DRUGS TO DRIVE SEGMENT GROWTH 141
10.3 NEUROLOGICAL DISEASES 142
10.3.1 COMPLEXITY OF NEUROGENERATIVE DISORDERS AND SHORTAGE OF DRUGS FOR PARKINSON’S DISEASE TO SPUR MARKET GROWTH 142
10.4 CARDIOVASCULAR DISEASES 144
10.4.1 RISING DEMAND FOR NOVEL CARDIOVASCULAR DRUGS TO DRIVE SEGMENT 144
10.5 METABOLIC DISEASES 145
10.5.1 RISING PREVALENCE OF DIABETES AND OBESITY TO SUPPORT MARKET GROWTH 145
10.6 INFECTIOUS DISEASES 146
10.6.1 RECENT EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITIES FOR INFECTIOUS DISEASES 146
10.7 IMMUNOLOGY DISEASES 147
10.7.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 147
10.8 OTHER DISEASES 148
11 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 150
11.1 INTRODUCTION 151
11.2 MACHINE LEARNING 151
11.2.1 DEEP LEARNING 153
11.2.1.1 Reduced chance of errors in clinical trials and enhanced data consistency to augment segment growth 153
11.2.2 SUPERVISED LEARNING 155
11.2.2.1 Supervised learning to focus on effective patient stratification, disease progression prediction, and biomarker identification 155
11.2.3 UNSUPERVISED LEARNING 156
11.2.3.1 Effective handling of complex and unstructured datasets to aid adoption in trial design and execution 156
11.2.4 REINFORCEMENT LEARNING 157
11.2.4.1 Dynamic learning capabilities to aid adoption in personalized medicine and precision oncology 157
11.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 158
?
11.3 NATURAL LANGUAGE PROCESSING 159
11.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO PROPEL GROWTH IN TRIAL MANAGEMENT 159
11.4 COMPUTER VISION 160
11.4.1 RISING NEED FOR REPRODUCIBLE ANALYSIS IN CLINICAL ENDPOINTS TO DRIVE MARKET 160
11.5 ROBOTIC PROCESS AUTOMATION 161
11.5.1 ROBOTIC PROCESS AUTOMATION TO ENHANCE OPERATIONAL EFFICIENCY
BY AUTOMATING ADMINISTRATIVE WORKFLOWS 161
11.6 OTHER TECHNOLOGIES 162
12 AI IN CLINICAL TRIALS MARKET, BY APPLICATION 163
12.1 INTRODUCTION 164
12.2 BIOMARKERS 164
12.2.1 INCREASING INVESTMENTS IN AI-BASED INNOVATION TO AID DEVELOPMENT OF PERSONALIZED HEALTHCARE SOLUTIONS 164
12.3 CELL & GENE THERAPY 165
12.3.1 HIGH PREVALENCE OF GENETIC DISORDERS AND TECHNOLOGICAL ADVANCEMENTS IN CAR-T THERAPIES TO DRIVE GROWTH 165
12.4 REGENERATIVE MEDICINES 166
12.4.1 INCREASED NEED FOR PRECISE MONITORING AND ADVANCEMENTS IN STEM CELL RESEARCH TO SPUR MARKET GROWTH 166
12.5 MEDICAL DEVICES & DIAGNOSTICS 167
12.5.1 NEED FOR REAL-TIME MONITORING AND REMOTE DATA ACQUISITION DURING TRIALS TO ACCELERATE MARKET GROWTH 167
13 AI IN CLINICAL TRIALS MARKET, BY END USER 169
13.1 INTRODUCTION 170
13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 170
13.2.1 HIGH R&D INVESTMENTS AND INCREASED REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH 170
13.3 RESEARCH INSTITUTES & LABORATORIES 171
13.3.1 INCREASED GOVERNMENT GRANTS AND COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH 171
13.4 HEALTHCARE PROVIDERS 172
13.4.1 ADVANCEMENTS IN PRECISION MEDICINES AND NEED FOR REAL-WORLD EVIDENCE IN CLINICAL RESEARCH TO DRIVE MARKET 172
13.5 CONTRACT RESEARCH ORGANIZATIONS 173
13.5.1 RISING DEMAND FOR OUTSOURCING CLINICAL TRIAL ACTIVITIES BY PHARMACEUTICAL COMPANIES TO AID MARKET GROWTH 173
13.6 MEDICAL DEVICE MANUFACTURERS 175
13.6.1 DEMAND FOR AI-DRIVEN DIAGNOSTICS AND MONITORING DEVICES FOR REMOTE CARE TO PROPEL MARKET GROWTH 175
?
14 AI IN CLINICAL TRIALS MARKET, BY REGION 176
14.1 INTRODUCTION 177
14.2 NORTH AMERICA 177
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 178
14.2.2 US 183
14.2.2.1 US to dominate North American AI in clinical trials market during study period 183
14.2.3 CANADA 188
14.2.3.1 Rising need for data standardization and increasing health expenditure to support market growth 188
14.3 EUROPE 192
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 192
14.3.2 UK 197
14.3.2.1 High R&D investment by government organizations to augment market growth 197
14.3.3 GERMANY 202
14.3.3.1 Increased focus on research activities and strategic developments
by pharma & biotech companies to drive market 202
14.3.4 FRANCE 206
14.3.4.1 Strong government support and focus on domestic drug research
to propel market growth 206
14.3.5 ITALY 211
14.3.5.1 Increased R&D investments from pharmaceutical companies and reduced time for drug approvals to fuel market growth 211
14.3.6 SPAIN 215
14.3.6.1 Increased technological investments by private organizations and integrated healthcare systems to spur market growth 215
14.3.7 REST OF EUROPE 219
14.4 ASIA PACIFIC 223
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 223
14.4.2 JAPAN 229
14.4.2.1 Well-established clinical trial infrastructure and advanced biomedical research to support market growth 229
14.4.3 CHINA 233
14.4.3.1 Low cost of clinical trials and availability of treatment-na?ve population to propel market growth 233
14.4.4 INDIA 238
14.4.4.1 Favorable government policies and high R&D expenditure by Indian pharmaceutical companies to spur market growth 238
14.4.5 REST OF ASIA PACIFIC 242
14.5 LATIN AMERICA 246
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 246
14.5.2 BRAZIL 251
14.5.2.1 Increasing governmental support for innovation and growing biotechnology sector to drive market 251
14.5.3 MEXICO 256
14.5.3.1 Strong technological and research capabilities in AI applications to fuel market growth 256
14.5.4 REST OF LATIN AMERICA 260
14.6 MIDDLE EAST & AFRICA 264
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 265
14.6.2 GCC COUNTRIES 269
14.6.2.1 Technological innovations and focus on precision medicines to augment market growth 269
14.6.3 REST OF MIDDLE EAST & AFRICA 274
15 COMPETITIVE LANDSCAPE 279
15.1 INTRODUCTION 279
15.2 KEY PLAYER STRATEGY/RIGHT TO WIN 279
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET 280
15.3 REVENUE ANALYSIS, 2019–2023 281
15.4 MARKET SHARE ANALYSIS, 2023 282
15.4.1 RANKING OF KEY MARKET PLAYERS 284
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 285
15.5.1 STARS 285
15.5.2 EMERGING LEADERS 285
15.5.3 PERVASIVE PLAYERS 285
15.5.4 PARTICIPANTS 285
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 287
15.5.5.1 Company footprint 287
15.5.5.2 Region footprint 288
15.5.5.3 Offering footprint 289
15.5.5.4 Function footprint 290
15.5.5.5 End-user footprint 291
15.6 COMPANY EVALUATION QUADRANT: STARTUP/SMES, 2023 292
15.6.1 PROGRESSIVE COMPANIES 292
15.6.2 RESPONSIVE COMPANIES 292
15.6.3 DYNAMIC COMPANIES 292
15.6.4 STARTING BLOCKS 292
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 294
15.7 COMPANY EVALUATION & FINANCIAL METRICS 296
15.8 BRAND/PRODUCT COMPARISON 297
15.9 COMPETITIVE SCENARIO 298
15.9.1 PRODUCT/SERVICE/SOLUTION LAUNCHES 298
15.9.2 DEALS 299
15.9.3 OTHER DEVELOPMENTS 300
16 COMPANY PROFILES 301
16.1 KEY PLAYERS 301
16.1.1 IQVIA INC. 301
16.1.1.1 Products/Services/Solutions offered 303
16.1.1.2 Recent developments 303
16.1.1.2.1 Solution launches 303
16.1.1.2.2 Deals 304
16.1.1.3 MnM view 304
16.1.1.3.1 Right to win 304
16.1.1.3.2 Strategic choices 305
16.1.1.3.3 Weaknesses & competitive threats 305
16.1.2 DASSAULT SYST?MES (MEDIDATA) 306
16.1.2.1 Business overview 306
16.1.2.2 Products/Services/Solutions offered 307
16.1.2.3 Recent developments 307
16.1.2.3.1 Solution launches 307
16.1.2.3.2 Deals 308
16.1.2.4 MnM view 308
16.1.2.4.1 Right to win 308
16.1.2.4.2 Strategic choices 308
16.1.2.4.3 Weaknesses & competitive threats 308
16.1.3 INSILICO MEDICINE 309
16.1.3.1 Business overview 309
16.1.3.2 Products/Services/Solutions offered 309
16.1.3.3 Recent developments 310
16.1.3.3.1 Other developments 310
16.1.3.4 MnM view 310
16.1.3.4.1 Right to win 310
16.1.3.4.2 Strategic choices 310
16.1.3.4.3 Weaknesses & competitive threats 311
16.1.4 TEMPUS AI, INC. 312
16.1.4.1 Business overview 312
16.1.4.2 Products/Services/Solutions offered 312
16.1.4.3 Recent developments 313
16.1.4.3.1 Solution launches 313
16.1.4.3.2 Deals 313
16.1.4.3.3 Other developments 315
16.1.4.4 MnM view 315
16.1.4.4.1 Right to win 315
16.1.4.4.2 Strategic choices 315
16.1.4.4.3 Weaknesses & competitive threats 315
?
16.1.5 NVIDIA CORPORATION 316
16.1.5.1 Business overview 316
16.1.5.2 Products/Services/Solutions offered 317
16.1.5.3 Recent developments 318
16.1.5.3.1 Product and service launches 318
16.1.5.3.2 Deals 319
16.1.5.4 MnM view 321
16.1.5.4.1 Right to win 321
16.1.5.4.2 Strategic choices 321
16.1.5.4.3 Weaknesses & competitive threats 321
16.1.6 SAAMA 322
16.1.6.1 Business overview 322
16.1.6.2 Products/Services/Solutions offered 322
16.1.6.3 Recent developments 323
16.1.6.3.1 Solution launches 323
16.1.6.3.2 Deals 324
16.1.7 PHESI 325
16.1.7.1 Business overview 325
16.1.7.2 Products/Services/Solutions offered 325
16.1.7.3 Recent developments 326
16.1.7.3.1 Solution launches 326
16.1.7.3.2 Deals 327
16.1.8 PATHAI, INC. 328
16.1.8.1 Business overview 328
16.1.8.2 Products/Services/Solutions offered 328
16.1.9 UNLEARN.AI, INC. 329
16.1.9.1 Business overview 329
16.1.9.2 Products/Services/Solutions offered 329
16.1.9.3 Recent developments 331
16.1.9.3.1 Solution launches 331
16.1.9.3.2 Deals 331
16.1.9.3.3 Other developments 332
16.1.10 DEEP6.AI 333
16.1.10.1 Business overview 333
16.1.10.2 Products/Services/Solutions offered 333
16.1.10.3 Recent developments 334
16.1.10.3.1 Solution launch 334
16.1.10.3.2 Deals 334
16.1.11 MICROSOFT 335
16.1.11.1 Business overview 335
16.1.11.2 Products/Services/Solutions offered 337
16.1.11.3 Recent developments 337
16.1.12 IBM 340
16.1.12.1 Business overview 340
16.1.12.2 Products/Services/Solutions offered 341
16.1.12.3 Recent developments 342
16.1.12.3.1 Deals 342
16.1.13 CONCERTAI 343
16.1.13.1 Business overview 343
16.1.13.2 Products/Services/Solutions offered 343
16.1.13.3 Recent developments 344
16.1.13.3.1 Solution launches 344
16.1.13.3.2 Deals 344
16.1.13.3.3 Other developments 345
16.1.14 AICURE 346
16.1.14.1 Business overview 346
16.1.14.2 Products/Services/Solutions offered 346
16.1.14.3 Recent developments 347
16.1.14.3.1 Service launches 347
16.1.14.3.2 Deals 347
16.1.15 MEDIAN TECHNOLOGIES 349
16.1.15.1 Business overview 349
16.1.15.2 Products/Services/Solutions offered 350
16.1.16 LANTERN PHARMA INC. 351
16.1.16.1 Business overview 351
16.1.16.2 Products/Services/Solutions offered 351
16.1.16.3 Recent developments 352
16.1.16.3.1 Deals 352
16.1.17 CITELINE, A NORSTELLA COMPANY 353
16.1.17.1 Business overview 353
16.1.17.2 Products/Services/Solutions offered 353
16.1.17.3 Recent developments 354
16.1.17.3.1 Solution launches 354
16.1.17.3.2 Deals 354
16.1.18 TRINETX, LLC 355
16.1.18.1 Business overview 355
16.1.18.2 Products/Services/Solutions offered 355
16.1.18.3 Recent developments 356
16.1.18.3.1 Deals 356
16.2 OTHER PLAYERS 357
16.2.1 REVIVEMED INC. 357
16.2.2 EURETOS 358
16.2.3 VERISIM LIFE 359
16.2.4 TRIOMICS 359
16.2.5 ARDIGEN 360
16.2.6 QUANTHEALTH LTD. 361
16.2.7 DEEP GENOMICS 362
17 APPENDIX 363
17.1 DISCUSSION GUIDE 363
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 369
17.3 CUSTOMIZATION OPTIONS 371
17.4 RELATED REPORTS 371
17.5 AUTHOR DETAILS 372

List of Figures

FIGURE 1 AI IN CLINICAL TRIALS MARKET: SEGMENTS CONSIDERED 34
FIGURE 2 AI IN CLINICAL TRIALS MARKET: YEARS CONSIDERED 37
FIGURE 3 AI IN CLINICAL TRIALS MARKET: RESEARCH DESIGN 39
FIGURE 4 AI IN CLINICAL TRIALS MARKET: KEY DATA FROM SECONDARY SOURCES 41
FIGURE 5 AI IN CLINICAL TRIALS MARKET: KEY PRIMARY SOURCES 42
FIGURE 6 AI IN CLINICAL TRIALS MARKET: KEY DATA FROM PRIMARY SOURCES 43
FIGURE 7 AI IN CLINICAL TRIALS MARKET: KEY INSIGHTS FROM PRIMARIES 44
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 44
FIGURE 9 MARKET SIZE ESTIMATION: SUPPLY-SIDE REVENUE SHARE ANALYSIS 45
FIGURE 10 AI IN CLINICAL TRIALS MARKET: TOP-DOWN APPROACH 46
FIGURE 11 AI IN CLINICAL TRIALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 48
FIGURE 13 AI IN CLINICAL TRIALS MARKET: DATA TRIANGULATION 49
FIGURE 14 AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2024 VS. 2030 (USD MILLION) 52
FIGURE 15 AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2024 VS. 2030 (USD MILLION) 53
FIGURE 16 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2024 VS. 2030 (USD MILLION) 53
FIGURE 17 AI IN CLINICAL TRIALS MARKET, BY PHASE, 2024 VS. 2030 (USD MILLION) 54
FIGURE 18 AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 55
FIGURE 19 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION) 56
FIGURE 20 AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2024 VS. 2030 (USD MILLION) 56
FIGURE 21 AI IN CLINICAL TRIALS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 57
FIGURE 22 AI IN CLINICAL TRIALS MARKET: REGIONAL SNAPSHOT 58
FIGURE 23 NEED FOR DATA STANDARDIZATION AND FAVORABLE GOVERNMENT
POLICIES TO DRIVE MARKET 59
FIGURE 24 NORTH AMERICA TO DOMINATE AI IN CLINICAL TRIALS MARKET DURING FORECAST PERIOD 60
FIGURE 25 US AND PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023 61
FIGURE 26 UK TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 62
FIGURE 27 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES
FROM 2024 TO 2029 63
FIGURE 28 AI IN CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES 64
FIGURE 29 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015–2023 66
FIGURE 30 HEALTHCARE SECURITY BREACHES OF 500+ RECORDS (2009–2023) 70
FIGURE 31 AI IN CLINICAL TRIALS MARKET: ECOSYSTEM ANALYSIS 75
FIGURE 32 AI IN CLINICAL TRIALS MARKET: VALUE CHAIN ANALYSIS 77
FIGURE 33 AI IN CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 79
FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR
TOP THREE END USERS 82
FIGURE 35 KEY BUYING CRITERIA FOR TOP THREE END USERS 83
FIGURE 36 PATENT PUBLICATION TRENDS IN AI IN CLINICAL TRIALS MARKET, 2015–2024 87
FIGURE 37 TOP APPLICANTS/OWNERS OF PATENTS AND NUMBER OF PATENTS GRANTED, JANUARY 2015–NOVEMBER 2024 88
FIGURE 38 AI IN CLINICAL TRIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 93
FIGURE 39 AI IN CLINICAL TRIALS MARKET: FUNDING AND NUMBER OF DEALS, 2022–2024 95
FIGURE 40 IMPACT OF AI/GEN AI ON AI-BASED CLINICAL TRIAL SOLUTIONS 96
FIGURE 41 IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 98
FIGURE 42 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET SNAPSHOT 178
FIGURE 43 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET SNAPSHOT 224
FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET, 2019–2023 (USD BILLION) 281
FIGURE 45 MARKET SHARE ANALYSIS IN AI IN CLINICAL TRIALS MARKET (2023) 282
FIGURE 46 RANKING OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET (2023) 284
FIGURE 47 AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 286
FIGURE 48 AI IN CLINICAL TRIALS MARKET: COMPANY FOOTPRINT 287
FIGURE 49 AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 293
FIGURE 50 EV/EBITDA OF KEY VENDORS 296
FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
AI IN CLINICAL TRIAL KEY VENDORS 296
FIGURE 52 AI IN CLINICAL TRIALS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 297
FIGURE 53 IQVIA INC.: COMPANY SNAPSHOT 302
FIGURE 54 DASSAULT SYST?MES (MEDIDATA): COMPANY SNAPSHOT 306
FIGURE 55 NVIDIA CORPORATION: COMPANY SNAPSHOT 317
FIGURE 56 MICROSOFT: COMPANY SNAPSHOT 336
FIGURE 57 IBM: COMPANY SNAPSHOT 341
FIGURE 58 MEDIAN TECHNOLOGIES: COMPANY SNAPSHOT 349

List of Tables

TABLE 1 AI IN CLINICAL TRIALS MARKET: INCLUSIONS & EXCLUSIONS 35
TABLE 2 AI IN CLINICAL TRIALS MARKET: STUDY ASSUMPTIONS 50
TABLE 3 AI IN CLINICAL TRIALS MARKET: RISK ASSESSMENT 51
TABLE 4 AI IN CLINICAL TRIALS MARKET: IMPACT ANALYSIS 65
TABLE 5 CASE STUDY 1: AI-POWERED APPROACH TO OVERCOME CHALLENGES IN
IPF DRUG DEVELOPMENT 75
TABLE 6 CASE STUDY 2: REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH
ADVANCED MATCHING NETWORKS 76
TABLE 7 CASE STUDY 3: BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS 77
TABLE 8 AI IN CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES 80
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE
END USERS (%) 82
TABLE 10 KEY BUYING CRITERIA FOR TOP THREE END USERS 83
TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 84
TABLE 12 NORTH AMERICA: REGULATORY FRAMEWORK 84
TABLE 13 EUROPE: REGULATORY FRAMEWORK 85
TABLE 14 ASIA PACIFIC: REGULATORY FRAMEWORK 86
TABLE 15 MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK 86
TABLE 16 LATIN AMERICA: REGULATORY FRAMEWORK 87
TABLE 17 AI IN CLINICAL TRIALS MARKET: LIST OF PATENTS/PATENT
APPLICATIONS, 2023–2024 89
TABLE 18 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023 91
TABLE 19 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022–2024 92
TABLE 20 AI IN CLINICAL TRIALS MARKET: KEY CONFERENCES & EVENTS JANUARY 2024–DECEMBER 2025 92
TABLE 21 AI IN CLINICAL TRIALS MARKET: UNMET NEEDS 94
TABLE 22 AI IN CLINICAL TRIALS MARKET: END-USER EXPECTATIONS 95
TABLE 23 AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 102
TABLE 24 AI IN CLINICAL TRIALS MARKET FOR END-TO-END SOLUTIONS BY COUNTRY, 2022–2030 (USD MILLION) 103
TABLE 25 AI IN CLINICAL TRIALS MARKET FOR NICHE SOLUTIONS, BY COUNTRY 2022–2030 (USD MILLION) 104
TABLE 26 AI IN CLINICAL TRIALS MARKET FOR TECHNOLOGY PROVIDERS, BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 27 AI IN CLINICAL TRIALS MARKET FOR SERVICES, BY COUNTRY 2022–2030 (USD MILLION) 106
TABLE 28 CONSULTING SERVICES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 107
TABLE 29 IMPLEMENTATION SERVICES & OUTGOING IT SUPPORT MARKET BY COUNTRY, 2022–2030 (USD MILLION) 108
TABLE 30 TRAINING & EDUCATION SERVICES MARKET, BY COUNTRY 2022–2030 (USD MILLION) 109
TABLE 31 POST-SALES & MAINTENANCE SERVICES MARKET, BY COUNTRY 2022–2030 (USD MILLION) 110
TABLE 32 AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 112
TABLE 33 AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY TYPE 2022–2030 (USD MILLION) 113
TABLE 34 AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY COUNTRY 2022–2030 (USD MILLION) 113
TABLE 35 PATIENT IDENTIFICATION & SCREENING MARKET, BY COUNTRY 2022–2030 (USD MILLION) 114
TABLE 36 PATIENT ENGAGEMENT & RETENTION MARKET, BY COUNTRY 2022–2030 (USD MILLION) 115
TABLE 37 SITE OPTIMIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116
TABLE 38 AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY TYPE, 2022–2030 (USD MILLION) 117
TABLE 39 AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 40 AI IN CLINICAL TRIALS MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 41 AI IN CLINICAL TRIALS MARKET FOR PREDICTIVE MODELING, BY COUNTRY 2022–2030 (USD MILLION) 120
TABLE 42 AI IN CLINICAL TRIALS MARKET FOR RISK MANAGEMENT, BY COUNTRY 2022–2030 (USD MILLION) 121
TABLE 43 AI IN CLINICAL TRIALS MARKET FOR DATA MANAGEMENT & QUALITY CONTROL BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 44 AI IN CLINICAL TRIALS MARKET FOR ADVERSE EVENT PREDICTION & DETECTION, BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 45 AI IN CLINICAL TRIALS MARKET FOR DRUG REPURPOSING, BY COUNTRY 2022–2030 (USD MILLION) 124
TABLE 46 AI IN CLINICAL TRIALS MARKET FOR REGULATORY COMPLIANCE BY COUNTRY, 2022–2030 (USD MILLION) 125
TABLE 47 AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 127
TABLE 48 AI IN PHASE 1 CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 128
TABLE 49 AI IN PHASE II CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 129
TABLE 50 AI IN PHASE III CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 130
TABLE 51 AI IN PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 131
TABLE 52 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 133
TABLE 53 AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS BY TYPE, 2022–2030 (USD MILLION) 134
TABLE 54 AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 55 PUBLIC CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 135
TABLE 56 PRIVATE CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 136
TABLE 57 MULTI CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 137
TABLE 58 HYBRID CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 138
TABLE 59 AI IN CLINICAL TRIALS MARKET FOR ON-PREMISES SOLUTIONS, BY COUNTRY, 2022–2030 (USD MILLION) 139
TABLE 60 AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION) 141
TABLE 61 AI IN CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY 2022–2030 (USD MILLION) 142
TABLE 62 AI IN CLINICAL TRIALS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 63 AI IN CLINICAL TRIALS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 64 AI IN CLINICAL TRIALS MARKET FOR METABOLIC DISEASES, BY COUNTRY 2022–2030 (USD MILLION) 145
TABLE 65 AI IN CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022–2030 (USD MILLION) 147
TABLE 66 AI IN CLINICAL TRIALS MARKET FOR IMMUNOLOGY DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 148
TABLE 67 AI IN CLINICAL TRIALS MARKET FOR OTHER DISEASES, BY COUNTRY 2022–2030 (USD MILLION) 149
TABLE 68 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 151
TABLE 69 AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY TYPE 2022–2030 (USD MILLION) 152
TABLE 70 AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY COUNTRY 2022–2030 (USD MILLION) 153
TABLE 71 DEEP LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 154
TABLE 72 SUPERVISED LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 155
TABLE 73 UNSUPERVISED LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 74 REINFORCEMENT LEARNING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 75 OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY COUNTRY 2022–2030 (USD MILLION) 158
TABLE 76 AI IN CLINICAL TRIALS MARKET FOR NATURAL LANGUAGE PROCESSING BY COUNTRY, 2022–2030 (USD MILLION) 159
TABLE 77 AI IN CLINICAL TRIALS MARKET FOR COMPUTER VISION, BY COUNTRY 2022–2030 (USD MILLION) 160
TABLE 78 AI IN CLINICAL TRIALS MARKET FOR ROBOTIC PROCESS AUTOMATION BY COUNTRY, 2022–2030 (USD MILLION) 161
TABLE 79 AI IN CLINICAL TRIALS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY 2022–2030 (USD MILLION) 162
TABLE 80 AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 164
TABLE 81 AI IN CLINICAL TRIALS MARKET FOR BIOMARKERS, BY COUNTRY 2022–2030 (USD MILLION) 165
TABLE 82 AI IN CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY 2022–2030 (USD MILLION) 166
TABLE 83 AI IN CLINICAL TRIALS MARKET FOR REGENERATIVE MEDICINES BY COUNTRY, 2022–2030 (USD MILLION) 167
TABLE 84 AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICES & DIAGNOSTICS BY COUNTRY, 2022–2030 (USD MILLION) 168
TABLE 85 AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 170
TABLE 86 AI IN CLINICAL TRIALS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION) 171
TABLE 87 AI IN CLINICAL TRIALS MARKET FOR RESEARCH INSTITUTES & LABORATORIES BY COUNTRY, 2022–2030 (USD MILLION) 172
TABLE 88 AI IN CLINICAL TRIALS MARKET FOR HEALTHCARE PROVIDERS BY COUNTRY, 2022–2030 (USD MILLION) 173
TABLE 89 RECENT ACQUISITIONS /COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS 174
TABLE 90 AI IN CLINICAL TRIALS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS BY COUNTRY, 2022–2030 (USD MILLION) 174
TABLE 91 AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 2022–2030 (USD MILLION) 175
TABLE 92 AI IN CLINICAL TRIALS MARKET, BY REGION, 2022–2030 (USD MILLION) 177
TABLE 93 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 179
TABLE 94 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 179
TABLE 95 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 179
TABLE 96 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 180
TABLE 97 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 180
TABLE 98 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 181
TABLE 99 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 181
TABLE 100 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 182
TABLE 101 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 182
TABLE 102 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 183
TABLE 103 US: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 184
TABLE 104 US: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 184
TABLE 105 US: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION) 185
TABLE 106 US: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 185
TABLE 107 US: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 186
TABLE 108 US: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 186
TABLE 109 US: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 187
TABLE 110 US: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 187
TABLE 111 CANADA: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 188
TABLE 112 CANADA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 188
TABLE 113 CANADA: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 189
TABLE 114 CANADA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 189
TABLE 115 CANADA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 190
TABLE 116 CANADA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 190
TABLE 117 CANADA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 191
TABLE 118 CANADA: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 191
TABLE 119 EUROPE: AI IN CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 193
TABLE 120 EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 193
TABLE 121 EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 194
TABLE 122 EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 194
TABLE 123 EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 195
TABLE 124 EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 195
TABLE 125 EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 196
TABLE 126 EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION,
2022–2030 (USD MILLION) 196
TABLE 127 EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 197
TABLE 128 UK: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 198
TABLE 129 UK: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 198
TABLE 130 UK: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION) 199
TABLE 131 UK: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 199
TABLE 132 UK: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 200
TABLE 133 UK: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 200
TABLE 134 UK: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 201
TABLE 135 UK: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 201
TABLE 136 GERMANY: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 202
TABLE 137 GERMANY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 203
TABLE 138 GERMANY: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 203
TABLE 139 GERMANY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 204
TABLE 140 GERMANY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 204
TABLE 141 GERMANY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 205
TABLE 142 GERMANY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 205
TABLE 143 GERMANY: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 206
TABLE 144 FRANCE: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 207
TABLE 145 FRANCE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 207
TABLE 146 FRANCE: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 208
TABLE 147 FRANCE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 208
TABLE 148 FRANCE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 209
TABLE 149 FRANCE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 209
TABLE 150 FRANCE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 210
TABLE 151 FRANCE: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 210
TABLE 152 ITALY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 211
TABLE 153 ITALY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 211
TABLE 154 ITALY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION) 212
TABLE 155 ITALY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 212
TABLE 156 ITALY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 213
TABLE 157 ITALY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 213
TABLE 158 ITALY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 214
TABLE 159 ITALY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 214
TABLE 160 SPAIN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 215
TABLE 161 SPAIN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 215
TABLE 162 SPAIN: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 216
TABLE 163 SPAIN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 216
TABLE 164 SPAIN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 217
TABLE 165 SPAIN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 217
TABLE 166 SPAIN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 218
TABLE 167 SPAIN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 218
TABLE 168 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 219
TABLE 169 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION) 219
TABLE 170 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 220
TABLE 171 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 220
TABLE 172 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 221
TABLE 173 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 221
TABLE 174 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 222
TABLE 175 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 222
TABLE 176 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 224
TABLE 177 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 225
TABLE 178 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 225
TABLE 179 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 226
TABLE 180 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 226
TABLE 181 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 227
TABLE 182 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 227
TABLE 183 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 228
TABLE 184 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 228
TABLE 185 JAPAN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 229
TABLE 186 JAPAN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 230
TABLE 187 JAPAN: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 230
TABLE 188 JAPAN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 231
TABLE 189 JAPAN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 231
TABLE 190 JAPAN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 232
TABLE 191 JAPAN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 232
TABLE 192 JAPAN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 233
TABLE 193 CHINA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 234
TABLE 194 CHINA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 234
TABLE 195 CHINA: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 235
TABLE 196 CHINA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 235
TABLE 197 CHINA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 236
TABLE 198 CHINA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 236
TABLE 199 CHINA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 237
TABLE 200 CHINA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 237
TABLE 201 INDIA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022–2030 (USD MILLION) 238
TABLE 202 INDIA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 238
TABLE 203 INDIA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022–2030 (USD MILLION) 239
TABLE 204 INDIA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 239
TABLE 205 INDIA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 240
TABLE 206 INDIA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 240
TABLE 207 INDIA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 241
TABLE 208 INDIA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 241
TABLE 209 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 242
TABLE 210 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION) 242
TABLE 211 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 243
TABLE 212 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 243
TABLE 213 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 244
TABLE 214 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 244
TABLE 215 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 245
TABLE 216 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 245
TABLE 217 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 247
TABLE 218 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 247
TABLE 219 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 248
TABLE 220 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 248
TABLE 221 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 249
TABLE 222 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 249
TABLE 223 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 250
TABLE 224 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 250
TABLE 225 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 251
TABLE 226 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 252
TABLE 227 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 252
TABLE 228 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 253
TABLE 229 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 253
TABLE 230 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 254
TABLE 231 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 254
TABLE 232 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 255
TABLE 233 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 255
TABLE 234 MEXICO: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 256
TABLE 235 MEXICO: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 257
TABLE 236 MEXICO: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 257
TABLE 237 MEXICO: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022–2030 (USD MILLION) 258
TABLE 238 MEXICO: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 258
TABLE 239 MEXICO: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 259
TABLE 240 MEXICO: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 259
TABLE 241 MEXICO: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 260
TABLE 242 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 260
TABLE 243 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION) 261
TABLE 244 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 261
TABLE 245 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 262
TABLE 246 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 262
TABLE 247 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 263
TABLE 248 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 263
TABLE 249 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 264
TABLE 250 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY REGION 2022–2030 (USD MILLION) 265
TABLE 251 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 265
TABLE 252 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022–2030 (USD MILLION) 266
TABLE 253 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 266
TABLE 254 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 267
TABLE 255 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 267
TABLE 256 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 268
TABLE 257 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 268
TABLE 258 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 269
TABLE 259 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY OFFERING 2022–2030 (USD MILLION) 270
TABLE 260 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE 2022–2030 (USD MILLION) 270
TABLE 261 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY INDICATION 2022–2030 (USD MILLION) 271
TABLE 262 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY PHASE 2022–2030 (USD MILLION) 271
TABLE 263 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 272
TABLE 264 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY 2022–2030 (USD MILLION) 272
TABLE 265 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY FUNCTION 2022–2030 (USD MILLION) 273
TABLE 266 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY END USER 2022–2030 (USD MILLION) 273
TABLE 267 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET BY OFFERING, 2022–2030 (USD MILLION) 274
TABLE 268 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET BY DEPLOYMENT MODE, 2022–2030 (USD MILLION) 275
TABLE 269 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET BY INDICATION, 2022–2030 (USD MILLION) 275
TABLE 270 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET BY PHASE, 2022–2030 (USD MILLION) 276
TABLE 271 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET BY APPLICATION, 2022–2030 (USD MILLION) 276
TABLE 272 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET BY TECHNOLOGY, 2022–2030 (USD MILLION) 277
TABLE 273 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022–2030 (USD MILLION) 277
TABLE 274 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022–2030 (USD MILLION) 278
TABLE 275 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN CLINICAL
TRIALS MARKET 280
TABLE 276 AI IN CLINICAL TRIALS MARKET: DEGREE OF COMPETITION 282
TABLE 277 AI IN CLINICAL TRIALS MARKET: REGION FOOTPRINT 288
TABLE 278 AI IN CLINICAL TRIALS MARKET: OFFERING FOOTPRINT 289
TABLE 279 AI IN CLINICAL TRIALS MARKET: FUNCTION FOOTPRINT 290
TABLE 280 AI IN CLINICAL TRIALS MARKET: END-USER FOOTPRINT 291
TABLE 281 AI IN CLINICAL TRIALS MARKET: DETAILED LI